According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. There are two broad indications from cancer metabolism-based therapies. One is targeted therapy and the other is experimental therapy. The target therapy indications are clinical studies of the drug type, systemic toxicity, and safety profile. On the other hand, the experimental indications are the research studies that have been done on various types of drugs like their effects on animals and also the results on humans. Cancer metabolism can be studied through the results obtained by using the appropriate drugs. The results are used by counselors to decide whether or not a particular treatment regimen will help the patient fight his or her disease. This is very important because the intensity of the challenge faced by patients with cancer is high and even if the patient manages to win the battle within the human body; it would still not guarantee him winning the struggle against the disease.
Request Free Sample Copy With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/961
Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound – Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Hence, providing orphan drug to the cancer patients would support to gain more value and share for cancer metabolism based therapeutics market.
Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.
Calithera Biosciences, Inc. announced novel cancer therapeutic drug named CB–839 in 2017. The FDA granted CB-839 as a Fast Track designation drug with the combination of everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is being evaluated in clinical trials phase I and II for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.
According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths U.S. Moreover, according to Cancer Research UK, approximately 3,102 new cases were diagnosed with acute myeloid leukemia (AML) in U.K. during 2014-2016, and around 2,598 deaths occurred during 2015-2017.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/961
According to American Cancer Society reports published in 2019 nearly 1,762,450 new cancer cases will be diagnosed in the U.S. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.
Moreover, growing strategic partnerships by key players engaged in cancer metabolism based therapeutics market to expand their market presence and product offering is projected to propel the market growth during the forecast period.
For instance, on January 2019, Celgene entered into a partnership agreement with Kyn Therapeutics for development of novel immune-oncology therapies. According to the partnership agreement Kyn Therapeutics will be responsible for research and development activities for phase I-b and Celgene will lead the commercialization and development of Kyn’s aryl hydrocarbon receptor (AHR) antagonist program and kynurenine-degrading enzyme program.
On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories
By Drug –
By Indication –
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
- Metastatic Renal Cell Carcinoma
The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/961
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 ECG Cable and ECG Lead Wires Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: ECG Cable and ECG Lead Wires Industry Impact
Chapter 2 ECG Cable and ECG Lead Wires Competition by Types, Applications, and Top Regions and Countries
2.1 ECG Cable and ECG Lead Wires (Volume and Value) by Type
2.3 ECG Cable and ECG Lead Wires (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 ECG Cable and ECG Lead Wires Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America ECG Cable and ECG Lead Wires Market Analysis
Chapter 6 East Asia ECG Cable and ECG Lead Wires Market Analysis
Chapter 7 Europe ECG Cable and ECG Lead Wires Market Analysis
Chapter 8 South Asia ECG Cable and ECG Lead Wires Market Analysis
Chapter 9 Southeast Asia ECG Cable and ECG Lead Wires Market Analysis
Chapter 10 Middle East ECG Cable and ECG Lead Wires Market Analysis
Chapter 11 Africa ECG Cable and ECG Lead Wires Market Analysis
Chapter 12 Oceania ECG Cable and ECG Lead Wires Market Analysis
Chapter 13 South America ECG Cable and ECG Lead Wires Market Analysis
Chapter 14 Company Profiles and Key Figures in ECG Cable and ECG Lead Wires Business
Chapter 15 ECG Cable and ECG Lead Wires Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027